Plus Therapeutics Q2 2024: ReSPECT-LM Phase 1 shows median OS 12 months; net loss $6.2M

PLUS THERAPEUTICS, INC.

2024-Q2 EPS reported -$1.45 revenue$2,956,000

ReSPECT-LM Phase 1 safe in 16 patients; median overall survival 12 months, 8 of 16 alive.
CNSide diagnostic met primary endpoint: helped clinical decisions in >90% of cases; tumor cell detection 80% vs 29% cytology.
Received $3.3M CPRIT grant in June 2024 for Rhenium (186Re) Obisbemeda development.
Cash $8.4M at June 30; H1 net loss $6.2M ($1.15/share) vs $6.3M ($2.60/share) year ago.
Upcoming: complete ReSPECT-LM Phase 1 single-dose, initiate multiple-dose Phase 1, and IND for pediatric trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.